|
US5686465A
(en)
|
1988-10-31 |
1997-11-11 |
Endorecherche Inc. |
Sex steroid activity inhibitors
|
|
US5395842A
(en)
|
1988-10-31 |
1995-03-07 |
Endorecherche Inc. |
Anti-estrogenic compounds and compositions
|
|
US5254568A
(en)
|
1990-08-09 |
1993-10-19 |
Council Of Scientific & Industrial Research |
Benzopyrans as antiestrogenic agents
|
|
EP0470310B1
(en)
*
|
1990-08-09 |
1995-11-29 |
Council of Scientific and Industrial Research |
Novel benzopyrans and process for their production
|
|
US6060503A
(en)
|
1991-12-02 |
2000-05-09 |
Endorecherche, Inc. |
Benzopyran-containing compounds and method for their use
|
|
DE69405491T2
(de)
|
1993-06-24 |
1998-02-19 |
Lilly Co Eli |
Antiöstrogene 2-Phenyl-3-Aroylbenzothiophene als hypoglykämische Mittel
|
|
US5446061A
(en)
|
1993-11-05 |
1995-08-29 |
Eli Lilly And Company |
Methods for lowering serum cholesterol
|
|
US5407947A
(en)
*
|
1993-11-05 |
1995-04-18 |
Eli Lilly And Company |
Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
|
|
US5416098A
(en)
|
1993-12-30 |
1995-05-16 |
Zymogenetics, Inc. |
Method for treating dermatitis and related conditions
|
|
US5389646A
(en)
|
1993-12-30 |
1995-02-14 |
Zymogenetics, Inc. |
Methods for treatment and prevention of bone loss using 2,3-benzopyrans
|
|
US5681835A
(en)
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
|
PL181304B1
(pl)
|
1994-07-22 |
2001-07-31 |
Lilly Co Eli |
Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
|
|
US5446071A
(en)
|
1994-11-18 |
1995-08-29 |
Eli Lilly And Company |
Methods for lowering serum cholesterol
|
|
US5637598A
(en)
|
1994-11-18 |
1997-06-10 |
Eli Lilly And Company |
Methods of inhibiting bone loss
|
|
US5980938A
(en)
|
1996-07-15 |
1999-11-09 |
Eli Lilly And Company |
Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
|
|
DK0937060T3
(da)
*
|
1996-10-28 |
2003-04-07 |
Novo Nordisk As |
Nye cis-3,4-chroman-derivater, der er nyttige i forebyggelsen eller behandlingen af østrogen-relaterede sygdomme eller syndromer
|
|
AU8102498A
(en)
|
1997-07-09 |
1999-02-08 |
Central Drug Research Institute |
Preparation of diaryl-benzopyrans
|
|
AU8102398A
(en)
|
1997-07-09 |
1999-02-08 |
Central Drug Research Institute |
(dl)-2,3-diaryl-2h-1-benzopyrans
|
|
DE69840126D1
(de)
|
1997-08-15 |
2008-11-27 |
Univ Duke |
Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
|
|
ID24568A
(id)
|
1997-11-06 |
2000-07-27 |
American Home Prod |
Kontrasepsi oral yang mengandung anti-estrogen plus progestin
|
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
|
KR20010042384A
(ko)
|
1998-03-30 |
2001-05-25 |
린다 에스. 스티븐슨 |
핵 수용체 보조활성제 결합을 위한 방법 및 화합물
|
|
JP2002516983A
(ja)
|
1998-03-30 |
2002-06-11 |
ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア |
核受容体活性を調節するための方法及び化合物
|
|
US7005428B1
(en)
|
1998-06-11 |
2006-02-28 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
|
US6465445B1
(en)
|
1998-06-11 |
2002-10-15 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
|
US6262270B1
(en)
*
|
1998-08-14 |
2001-07-17 |
Schering Corporation |
Enantioselective synthesis
|
|
EP1104414B1
(en)
|
1998-08-14 |
2003-02-12 |
Schering Corporation |
Enantioselective synthesis
|
|
AR021719A1
(es)
|
1998-12-18 |
2002-07-31 |
Schering Corp |
Composicion farmaceutica oral antiestrogenica.
|
|
US6638727B1
(en)
|
1999-01-26 |
2003-10-28 |
Cytyc Health Corporation |
Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
|
|
US6716452B1
(en)
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
DE19916419B4
(de)
|
1999-04-08 |
2005-06-16 |
Schering Ag |
Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
|
|
CA2376158C
(en)
|
1999-07-06 |
2011-03-15 |
Endorecherche, Inc. |
Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain
|
|
AU7896100A
(en)
|
1999-10-14 |
2001-04-23 |
Endorecherche Inc. |
Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
|
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
|
CO5251465A1
(es)
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
|
BR0108107A
(pt)
|
2000-01-28 |
2003-03-11 |
Endorech Inc |
Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação
|
|
WO2001063292A2
(en)
|
2000-02-22 |
2001-08-30 |
Board Of Regents, The University Of Texas System |
Compositions and methods of use of het, a novel modulator of estrogen action
|
|
DE10013782A1
(de)
*
|
2000-03-15 |
2001-10-18 |
Schering Ag |
4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
US6528681B2
(en)
|
2000-04-05 |
2003-03-04 |
Bristol-Meyers Squibb Pharma Company |
Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
|
|
US20020013327A1
(en)
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
US8119138B2
(en)
|
2000-05-10 |
2012-02-21 |
Signe Biopharma Inc. |
Anti-estrogen and immune modulator combinations for treating breast cancer
|
|
US7863011B2
(en)
|
2000-05-10 |
2011-01-04 |
Signe Biopharma, Inc. |
Screening method for predicting susceptibility to breast cancer
|
|
EP1177787A3
(en)
|
2000-07-28 |
2003-09-10 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating cataracts
|
|
JP2004507465A
(ja)
|
2000-08-11 |
2004-03-11 |
ワイス |
エストロゲン受容体陽性癌腫の治療方法
|
|
US20020099013A1
(en)
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
|
NZ524104A
(en)
|
2000-09-08 |
2004-12-24 |
Pharmacia Italia S |
Exemestane as chemopreventing agent
|
|
EP1192945A3
(en)
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
|
WO2002030429A1
(en)
|
2000-10-06 |
2002-04-18 |
Biomedicines, Inc. |
Combination therapy for the treatment of estrogen-sensitive disease
|
|
IL145838A
(en)
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
|
|
IL154984A0
(en)
|
2000-10-19 |
2003-10-31 |
Merck & Co Inc |
Estrogen receptor modulators
|
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
WO2002032373A2
(en)
|
2000-10-19 |
2002-04-25 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
|
MXPA03006607A
(es)
|
2001-01-26 |
2003-09-22 |
Upjohn Co |
Metodo combinado para tratar trastornos dependientes de hormonas.
|
|
US20040082557A1
(en)
|
2001-01-26 |
2004-04-29 |
Wajszczuk Charles Paul |
Methods for treating estrogen-dependent disorders
|
|
GB2374412A
(en)
|
2001-04-11 |
2002-10-16 |
Karobio Ab |
Hypertension treatment and assay
|
|
PL374215A1
(en)
|
2001-08-11 |
2005-10-03 |
Bristol-Myers Squibb Pharma Company |
Selective estrogen receptor modulators
|
|
EP1429779A2
(en)
|
2001-09-21 |
2004-06-23 |
Merck & Co., Inc. |
Androstanes as androgen receptor modulators
|
|
CA2462456C
(en)
|
2001-10-03 |
2010-05-04 |
Merck & Co., Inc. |
Androstane 17-beta-carboxamides as androgen receptor modulators
|
|
EP1435967A2
(en)
|
2001-10-10 |
2004-07-14 |
Pharmacia Italia S.p.A. |
Methods for preventing and treating bone loss with steroid compounds
|
|
ES2291507T3
(es)
|
2001-10-19 |
2008-03-01 |
MERCK & CO., INC. |
Moduladores de receptor de androgenos y procedimientos de uso de los mismos.
|
|
EP1467998B1
(en)
*
|
2001-12-19 |
2006-03-29 |
Ortho-Mcneil Pharmaceutical, Inc. |
Tetracyclic heterocompounds as estrogen receptor modulators
|
|
US7105679B2
(en)
*
|
2001-12-19 |
2006-09-12 |
Kanojia Ramesh M |
Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
|
|
JP2005524630A
(ja)
|
2002-01-14 |
2005-08-18 |
ノルディック・ビオサイエンス・エー／エス |
エストロゲン受容体を介する軟骨破壊の抑制
|
|
WO2003070253A1
(en)
|
2002-02-21 |
2003-08-28 |
Pantarhei Bioscience B.V. |
Estrogenic component for treating decreased libido in women
|
|
PL372920A1
(en)
|
2002-03-13 |
2005-08-08 |
Merck & Co,Inc. |
Fluorinated 4-azasteroid derivatives as androgen receptor modulators
|
|
CA2478640A1
(en)
|
2002-03-13 |
2003-09-18 |
F. Hoffmann-La Roche Ag |
Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
|
|
US20030225132A1
(en)
|
2002-04-11 |
2003-12-04 |
Dininno Frank P. |
Estrogen receptor modulators
|
|
DK1501819T3
(da)
|
2002-04-24 |
2011-01-10 |
Merck Sharp & Dohme |
Østrogenreceptormodulatorer
|
|
CA2484173A1
(en)
|
2002-04-30 |
2003-11-13 |
Merck & Co., Inc. |
4-azasteroid derivatives as androgen receptor modulators
|
|
RU2005101635A
(ru)
|
2002-06-25 |
2005-08-10 |
Уайт (Us) |
Применение производных тиооксиндола в терапии гормонозависимых состояний
|
|
RU2005101638A
(ru)
|
2002-06-25 |
2006-01-20 |
Уайт (Us) |
Использование циклокарбаматных производных для лечения гормонзависимых состояний
|
|
US7622592B2
(en)
|
2002-11-01 |
2009-11-24 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
|
WO2004091488A2
(en)
|
2003-04-14 |
2004-10-28 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
EP1622630B1
(en)
|
2003-05-07 |
2012-08-29 |
Osteologix A/S |
Strontium combinations for the prophylaxis/treatment of cartilage and/or bone conditions
|
|
CA2524409C
(en)
|
2003-05-07 |
2011-12-20 |
Merck & Co., Inc. |
Androgen receptor modulators and methods of use thereof
|
|
US20040248989A1
(en)
|
2003-06-05 |
2004-12-09 |
Risto Santti |
Method for the treatment or prevention of lower urinary tract symptoms
|
|
US7696217B2
(en)
|
2003-06-30 |
2010-04-13 |
Merck Sharp & Dohme Corp. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
CA2530182A1
(en)
|
2003-06-30 |
2005-01-20 |
Merck & Co., Inc. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
AU2004255200A1
(en)
|
2003-06-30 |
2005-01-20 |
Merck & Co., Inc. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
CA2530047A1
(en)
|
2003-06-30 |
2005-02-03 |
Merck & Co., Inc. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
EP1670483A4
(en)
|
2003-09-10 |
2010-02-17 |
Merck & Co Inc |
17-heterocyclic 4-azasteroid derivatives as androgen receptor modules
|
|
US7446110B2
(en)
|
2003-09-10 |
2008-11-04 |
Merck & Co., Inc. |
17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
|
|
EP1692127B1
(en)
|
2003-10-08 |
2008-07-02 |
Smithkline Beecham Corporation |
Triphenylethylene compounds as selective estrogen receptor modulators
|
|
WO2005044988A2
(en)
|
2003-10-31 |
2005-05-19 |
Merck & Co., Inc. |
21-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
|
|
WO2005073190A1
(en)
|
2004-01-29 |
2005-08-11 |
Eli Lilly And Company |
Selective estrogen receptor modulators
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
US20090035315A1
(en)
|
2004-06-17 |
2009-02-05 |
Stephan Christgau |
Method of Improving Treatments in Rheumatic and Arthritic Diseases
|
|
WO2005123130A2
(en)
|
2004-06-17 |
2005-12-29 |
Osteologix A/S |
Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
|
|
WO2006024689A1
(en)
|
2004-09-03 |
2006-03-09 |
Hormos Medical Ltd. |
Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency
|
|
US8835413B2
(en)
|
2004-10-20 |
2014-09-16 |
Endorecherche, Inc. |
Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
|
|
WO2006084937A1
(en)
|
2005-02-14 |
2006-08-17 |
Leskelae Hannu-Ville |
Method for diagnosing and treating women with increased response to hormonal replacement therapy
|
|
US20070078114A1
(en)
|
2005-09-02 |
2007-04-05 |
Myriad Genetics, Incorporated |
Combination therapy for alzheimer's disease and other diseases
|
|
WO2007098090A2
(en)
|
2006-02-17 |
2007-08-30 |
Novacea, Inc. |
Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators
|
|
US20080268041A1
(en)
|
2007-04-23 |
2008-10-30 |
Jens Hoffmann |
Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
|
|
DE102007026877A1
(de)
|
2007-06-08 |
2008-12-11 |
Bayer Schering Pharma Aktiengesellschaft |
Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker
|
|
WO2009143309A2
(en)
|
2008-05-21 |
2009-11-26 |
Trustees Of Dartmouth College |
Female reproductive tract and anal prophylaxes
|
|
WO2010107474A1
(en)
|
2009-03-16 |
2010-09-23 |
The Research Foundation Of State University Of New York |
Antiestrogens for breast cancer therapy
|
|
US20100317635A1
(en)
|
2009-06-16 |
2010-12-16 |
Endorecherche, Inc. |
Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
|
|
RS56042B1
(sr)
*
|
2010-06-10 |
2017-09-29 |
Seragon Pharmaceuticals Inc |
Modulatori estrogenih receptora i njihove upotrebe
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
DE102010030538A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Schering Pharma Aktiengesellschaft |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
CA2819299A1
(en)
|
2010-12-24 |
2012-06-28 |
Merck Sharp & Dohme B.V. |
N-substituted azetidine derivatives
|
|
WO2013090829A1
(en)
|
2011-12-14 |
2013-06-20 |
Aragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
|
EP2791128A4
(en)
|
2011-12-16 |
2015-04-22 |
Olema Pharmaceuticals Inc |
NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
|